The invention discloses a
lymphoblastic leukemia CAR-T (
Chimeric Antigen Receptor-
T Cell Immunotherapy) therapy carrier based on an OCTS (One CAR with Two SeFvs) technology. The
lymphoblastic leukemia CAR-T therapy carrier comprises a
lentivirus skeleton
plasma, a human EF1alpha
promoter, an OCTS chimeric
receptor structural domain and an IL6R single-chain
antibody, wherein the OCTS chimeric
receptor structural domain comprises a CD8 leader chimeric
receptor signal peptide and two groups of single-chain antibodies; the first group of single-chain antibodies is selected from any one of the following four groups of single-chain antibodies: a CD20 single-chain
antibody light chain VL and a CD20 single-chain
antibody heavy chain VH, a CD22 single-chain antibody light chain VL and a CD22 single-chain antibody
heavy chain VH, a CD30 single-chain antibody light chain VL and a CD30 single-chain antibody
heavy chain VH, and a CD123 single-chain antibody light chain VL and a CD123 single-chain antibody heavy chain VH; and the second group of the single-chain antibodies is a CD19 single-chain antibody light chain VL and a CD19 single-chain antibody heavy chain VH, an antibody Inner-
Linker, a single-chain antibody Inter-
Linker, a CD8-Hinge chimeric receptor
linker, a CD8 Transmembrane chimeric receptor transmembrane zone, a TCR (
T Cell Receptor) chimeric receptor
T cell activation domain and a chimeric receptor co-stimulator zone. Besides, the invention discloses a constructing method for the carrier and application of the carrier to preparation of a
drug for treating
lymphoblastic leukemia.